Koh Jin Sung, Joo Moon Kyung, Park Jong-Jae, Yoo Hyo Soon, Choi Byung Il, Lee Beom Jae, Chun Hoon Jai, Lee Sang Woo
1Division of Gastroenterology, Department of Internal Medicine, Korea University College of Medicine Guro Hospital, 148, Gurodong-ro, Guro-gu, Seoul, 152-703 Republic of Korea.
2Division of Gastroenterology, Department of Internal Medicine, Korea University College of Medicine Anam Hospital, 73, Inchon-ro, Seongbuk-gu, Seoul, 136-705 Republic of Korea.
Cell Biosci. 2018 Sep 6;8:50. doi: 10.1186/s13578-018-0248-9. eCollection 2018.
We investigated the inhibitory effect of pantoprazole on signal transducer and activator of transcription 3 (STAT3) activity and invasiveness of gastric adenocarcinoma cells, and the role of SH2-containing protein tyrosine phosphatase 1 (SHP-1) in mediating role.
We used AGS and MKN-28 cells because of reduced SHP-1 and preserved p-STAT3 expression. Western blot, wound closure assay, Matrigel invasion assay and 3-D culture invasion assay were performed. Pharmacologic inhibitor of SHP-1 and siRNA were used for validation of the role of SHP-1.
We observed that pantoprazole at 40, 80, and 160 μg/ml upregulated SHP-1 and downregulated p-STAT3 expression in a dose-dependent manner in AGS and MKN-28 cells. Furthermore, pantoprazole significantly downregulated mesenchymal markers (Snail1 and vimentin), upregulated epithelial marker (E-cadherin), and inhibited migration and invasion of AGS and MKN-28 cells. To validate the role of SHP-1 in inhibition of STAT3 activity by pantoprazole in gastric cancer cells, we performed pharmacologic inhibition (pervanadate) or knockdown of SHP-1 before pantoprazole treatment, which significantly attenuated the suppression of p-STAT3 and anti-migration and invasion effect by pantoprazole in AGS cells. In xenograft tumor model, tumor volume was significantly reduced by intraperitoneal injection of pantoprazole, with upregulation of SHP-1 and downregulation of p-STAT3, which were attenuated by concomitant injection of pervanadate.
Our data suggest that the inhibitory effect of pantoprazole on cellular migration and invasion might be through inducing SHP-1 in gastric cancer cells.
我们研究了泮托拉唑对胃腺癌细胞信号转导子和转录激活子3(STAT3)活性及侵袭性的抑制作用,以及含SH2结构域的蛋白酪氨酸磷酸酶1(SHP-1)在介导该作用中的角色。
由于AGS和MKN-28细胞中SHP-1表达降低而p-STAT3表达保留,故使用这两种细胞。进行了蛋白质免疫印迹法、伤口愈合试验、基质胶侵袭试验和三维培养侵袭试验。使用SHP-1的药理抑制剂和小干扰RNA来验证SHP-1的作用。
我们观察到,在AGS和MKN-28细胞中,40、80和160μg/ml的泮托拉唑以剂量依赖性方式上调SHP-1并下调p-STAT3表达。此外,泮托拉唑显著下调间充质标志物(Snail1和波形蛋白),上调上皮标志物(E-钙黏蛋白),并抑制AGS和MKN-28细胞的迁移和侵袭。为了验证SHP-1在泮托拉唑抑制胃癌细胞STAT3活性中的作用,我们在泮托拉唑处理前进行了药理抑制(过钒酸钠)或SHP-1敲低,这显著减弱了泮托拉唑对AGS细胞中p-STAT3的抑制作用以及抗迁移和侵袭作用。在异种移植肿瘤模型中,腹腔注射泮托拉唑可显著减小肿瘤体积,同时上调SHP-1并下调p-STAT3,而同时注射过钒酸钠可减弱这些作用。
我们的数据表明,泮托拉唑对细胞迁移和侵袭的抑制作用可能是通过诱导胃癌细胞中的SHP-1实现的。